Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPIA | P62937 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7522460 | 0.91 | MAPT (0.42) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL7520700 | 0.87 | MAPT (0.45) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL7519624 | 0.79 | MAPT (0.50) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL7526950 | 0.79 | PPIA (0.43) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL7515289 | 0.77 | MAPT (0.45) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL7523567 | 0.74 | MEN1 (0.50) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL7517108 | 0.72 | MEN1 (0.38) | ALDH1A1KMT2AMEN1LMNAIDO1 | |
| SCHEMBL7518438 | 0.72 | EPHX1 (0.61) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL7525033 | 0.69 | RAB9A (0.56) | ALDH1A1MAPTKMT2AMEN1GAA | |
| SCHEMBL7524987 | 0.69 | PPIA (0.46) | ALDH1A1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | ROCHE DIAGNOSTICS GMBH | 2002-05-16 | — | — | US | disclosed |
| US-6333346-B1 | AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
| EP-1009747-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | Roche Diagnostics GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012917-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | UTS2R, SRD5A2, SRD5A1 | ALDH1A1 223/4885MAPT 4634/4885KMT2A 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.